التفاصيل البيبلوغرافية
| العنوان: |
Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. |
| المؤلفون: |
Los-Arcos, Ibai, Iacoboni, Gloria, Aguilar-Guisado, Manuela, Alsina-Manrique, Laia, Díaz de Heredia, Cristina, Fortuny-Guasch, Claudia, García-Cadenas, Irene, García-Vidal, Carolina, González-Vicent, Marta, Hernani, Rafael, Kwon, Mi, Machado, Marina, Martínez-Gómez, Xavier, Maldonado, Valentín Ortiz, Pla, Carolina Pinto, Piñana, José Luis, Pomar, Virginia, Reguera-Ortega, Juan Luis, Salavert, Miguel, Soler-Palacín, Pere |
| المصدر: |
Infection; Apr2021, Vol. 49 Issue 2, p215-231, 17p, 1 Diagram, 3 Charts, 1 Graph |
| مصطلحات موضوعية: |
MEDICAL screening, PATIENT monitoring, PREVENTIVE health services, ANTIBIOTIC prophylaxis |
| مستخلص: |
Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both hematological and non-hematological diseases. Most of the patients receiving CAR-T therapy will develop fever at some point after infusion, mainly due to cytokine release syndrome (CRS). The onset of CRS is often indistinguishable from an infection, which makes management of these patients challenging. In addition to the lymphodepleting chemotherapy and CAR T cells, the treatment of complications with corticosteroids and/or tocilizumab increases the risk of infection in these patients. Data regarding incidence, risk factors and prevention of infections in patients receiving CAR-T cell therapy are scarce. To assist in patient care, a multidisciplinary team from hospitals designated by the Spanish Ministry of Health to perform CAR-T therapy prepared these recommendations. We reviewed the literature on the incidence, risk factors, and management of infections in adult and pediatric patients receiving CAR-T cell treatment. Recommendations cover different areas: monitoring and treatment of hypogammaglobulinemia, prevention, prophylaxis, and management of bacterial, viral, and fungal infections as well as vaccination prior and after CAR-T cell therapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Infection is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
